Integrating New Evidence on ASCVD and Microvascular Risk Reduction with Omega-3 Fatty Acids

SUPPORT STATEMENT
Supported by an unrestricted educational grant from Amarin Pharma, Inc.

18:30 – 18:35

Welcome, Introductions, Program Overview

Dirk Müller-Wieland (GER)

18:35 – 18:55

New Clinical Evidence of Omega-3 Fatty Acids on ASCVD Event Reduction

Dirk Müller-Wieland (GER)

18:55 – 19:15

Real-world Clinical Implications on Reducing ASCVD Events

Handrean Soran (UK)

19:15 – 19:30

Panel Discussion and Q&A

Handrean Soran (UK)
Dirk Müller-Wieland (GER)

Closing Comments

Dirk Müller-Wieland (GER)
Handrean Soran (UK)

Learning Objectives

At the conclusion of this activity, learners should be better able to:

  • Describe the spectrum of large-scale outcomes trials of omega-3 fatty acids on ASCVD events.
  • Appreciate the differences between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements.